N2004-03: Intravenous Fenretinide in Treating Young Patients With Recurrent or Resistant Neuroblastoma

Completed · Phase 1

Conditions studied: Neuroblastoma

In brief

RATIONALE: Drugs used in chemotherapy, such as fenretinide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase I trial is studying the side effects and best dose of intravenous fenretinide in treating young patients with recurrent or resistant neuroblastoma.

Key facts

Study ID
NCT00646230
Run by
New Approaches to Neuroblastoma Therapy Consortium
People needed
17
Starts
2006-12-01
Expected to finish
2012-03-01
Last updated by the study team
2026-04-14

Who can join

Age: any, up to 30. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.